Campbell's trades at a deeply distressed valuation of 7.7x EV/EBITDA and a forward P/E of 9, pricing in severe secular headwinds from GLP-1 adoption and processed food volume declines. While the 7.75% dividend yield and potential for strategic divestitures offer a floor, the stock remains a 'show-me' story given FY25 net income fell to $602M from $858M in FY23 and total debt ballooned to $7.2B. A hold is warranted until the upcoming Q3 FY26 report provides clarity on whether cost inflation is being managed and organic sales are stabilizing.
Persistent Input Cost Inflation
Transport and soft commodity costs continue to pressure margins, and CPB's ability to pass these through to consumers remains uncertain in a weak volume environment.
Elevated Leverage
Total debt stands at $7.2B against $3.9B in equity, limiting financial flexibility and making the equity highly sensitive to any EBITDA deterioration.
Secular Demand Erosion
GLP-1 medicines are structurally reducing demand for processed and packaged foods, directly threatening CPB's core Meals & Beverages and Snacks segments.
Insider Distribution Overhang
A large 17.3M share disposition by a Dorrance family trust in March 2026 signals potential ongoing selling pressure from controlling shareholders.